Liothyronine: Pediatric drug information

(For additional information see "Liothyronine: Drug information" and see "Liothyronine: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

ALERT: US Boxed Warning

Weight reduction:

Thyroid hormones, including liothyronine, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines, such as those used for their anorectic effects.

Brand Names: US

Cytomel;
Triostat [DSC]

Brand Names: Canada

Cytomel;
TEVA-Liothyronine

Therapeutic Category

Thyroid Product

Dosing: Neonatal

Congenital hypothyroidism

Congenital hypothyroidism: Oral: 5 mcg/day; increase by 5 mcg every 3 days to a maximum dosage of 20 mcg/day; Note: AAP recommends levothyroxine over liothyronine for treatment of hypothyroidism in neonates (Ref)

Postcardiac surgery replacement

Postcardiac surgery replacement: Very limited data available: Continuous IV infusion: 0.05 to 0.15 mcg/kg/hour adjusted to maintain a serum T₃ concentration 80 to 200 ng/dL; dosing based on experience in five neonates who, on postoperative days 0 to 2, required mechanical ventilation and exhibited total serum T₃ <60 ng/dL (Ref)

Dosing: Pediatric

Congenital hypothyroidism

Congenital hypothyroidism: Note: Guidelines do not recommend routine use of liothyronine over levothyroxine monotherapy in the management of hypothyroidism (Ref). Infants, Children, and Adolescents: Oral: Initial: 5 mcg/day; increase by 5 mcg every 3 to 4 days

Usual maintenance dose:

Infants: 20 mcg/day

Children 1 to 3 years: 50 mcg/day

Children >3 years and Adolescents: 25 to 75 mcg/day

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Liothyronine undergoes substantial renal excretion.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Adult

(For additional information see "Liothyronine: Drug information")

Antidepressant augmentation

Antidepressant augmentation (off-label use): Oral: Initial: 25 mcg/day; may be increased to 50 mcg/day after ~1 week based on response and tolerability (Ref). Dose ranges of 20 to 62.5 mcg/day have been studied in clinical trials (Ref). Note: The duration of treatment has not been well studied (Ref). If the patient has a history of multiple episodes or significant treatment resistance, long-term maintenance treatment is reasonable if there are no symptoms of hyperthyroidism and no known cardiac disease (Ref).

Deceased organ donor management

Deceased organ donor management (hormonal replacement therapy) (off-label use): Note: Use in hemodynamically unstable patients and/or in potential cardiac donors with a left ventricular ejection fraction <45%. May be used alone or as part of combination hormone therapy (Ref).

IV: 4 mcg bolus, followed by a continuous infusion of 3 mcg/hour (Ref).

Diagnostic aid, T₃suppression test

Diagnostic aid, T₃ suppression test: Oral: 75 to 100 mcg once daily for 7 days. Radioactive iodide uptake is determined before and after administration.

Hypothyroidism, primary

Hypothyroidism, primary (adjunctive agent):

Note: May be considered as an adjunct to levothyroxine in patients with persistent symptoms despite normal TSH levels who underwent thyroidectomy or radioiodine ablation, or whose serum T₃ levels are at or below the lower end of the reference range (Ref). Avoid use in patients who are at risk for arrhythmia, are older (eg, >60 years of age), or are pregnant (Ref). Use is not recommended in patients with secondary hypothyroidism (eg, due to hypopituitarism) due to limited data (Ref). Patient should be under the care of a clinician experienced with the use of levothyroxine and liothyronine combination therapy for this condition.

Oral: Initial: ~5% to 6% of the current daily levothyroxine dose (rounded to the nearest 5 mcg/day increment), typically administered in 2 divided daily doses; usual dose range: 5 to 12.5 mcg/day in 2 divided doses. When liothyronine is initiated, reduce the daily levothyroxine dose to 80% to 85% of the original dose. The final levothyroxine to liothyronine dose ratio should be approximately 13:1 to 16:1 (Ref); example dosing is as follows:

**Switching From Levothyroxine Monotherapy To Combination Therapy With Levothyroxine And Liothyronine^a**
Current levothyroxine dose	New combination regimen with levothyroxine and liothyronine^b
Current levothyroxine dose	New levothyroxine dose	New liothyronine dose
^a Adapted with permission from: Ross DS. Treatment of primary hypothyroidism in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed March 2, 2022. Copyright © 2022 UpToDate, Inc. and its affiliates and/or licensors. All rights reserved.
^bFor use as separate levothyroxine and liothyronine products according to the above conversions. Commercially available combination products are not recommended because they contain a 4:1 ratio mixture of levothyroxine and liothyronine that delivers a supraphysiologic liothyronine dose relative to levothyroxine (ETA [Wiersinga 2012]; Ross 2022).
75 to 100 mcg/day	50 to 75 mcg/day	2.5 mcg twice daily
112 to 137 mcg/day	88 to 112 mcg/day	2.5 mcg 3 times daily or 5 mcg every morning and 2.5 mcg every evening
150 to 175 mcg/day	112 to 137 mcg/day	5 mcg twice daily
200 to 250 mcg/day	150 to 200 mcg/day	7.5 mcg every morning and 5 mcg every evening

Dosage adjustment: Adjust the levothyroxine and/or liothyronine dose every 6 weeks if needed based on TSH levels while maintaining an approximate 13:1 to 16:1 dose ratio of levothyroxine to liothyronine (Ref). An example dosage adjustment strategy is as follows:

TSH above target: If TSH is <10 milliunits/L, increase the levothyroxine dose only; if TSH is ≥10 milliunits/L, also increase the liothyronine dose (eg, by 2.5 mcg/day) (Ref).

TSH below target: If TSH is detectable, generally reduce the liothyronine dose (eg, by 2.5 mcg/day); if TSH is fully suppressed, reduce both levothyroxine and liothyronine doses (Ref).

Duration of therapy: Combination therapy with liothyronine and levothyroxine may be continued indefinitely in patients whose hypothyroid symptoms improve; if hypothyroid symptoms persist after 3 months of euthyroidism with combination therapy, consider switching back to levothyroxine monotherapy (Ref).

Myxedema coma

Myxedema coma (adjunct to levothyroxine): IV: Initial loading dose of 5 to 20 mcg as a slow bolus, followed by 2.5 to 10 mcg every 8 hours until the patient improves (eg, regains consciousness) and can transition to oral levothyroxine; consider doses on the lower end of the dosing range for smaller or older patients and those with a history of or who are at risk for coronary artery disease or arrhythmia; concomitant glucocorticoid therapy (eg, stress doses of hydrocortisone) is required until the possibility of coexisting adrenal insufficiency is excluded (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Liothyronine undergoes substantial renal excretion.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for liothyronine sodium injection, unless otherwise noted.

1% to 10%:

Cardiovascular: Acute myocardial infarction (≤2%), angina pectoris (≤1%), cardiac arrhythmia (6%), heart failure (≤1%), hypertension (≤1%), hypotension (≤2%), phlebitis (≤1%), tachycardia (3%)

Nervous system: Twitching (≤1%)

Miscellaneous: Fever (≤1%)

Postmarketing: Dermatologic: Allergic skin reaction (tablets)

Contraindications

Injection: Hypersensitivity to liothyronine sodium or any component of the formulation; uncorrected adrenal insufficiency; untreated thyrotoxicosis; concurrent use with artificial rewarming of patient

Oral: Uncorrected adrenal insufficiency

Canadian labeling: Additional contraindications (not in the US labeling): Acute myocardial infarction

Warnings/Precautions

Disease-related concerns:

• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Treatment with glucocorticoids should precede thyroid replacement therapy in patients with adrenal insufficiency.

• Cardiovascular disease: Use reduced initial dosage and conservative dose titration in patients with cardiovascular disease. Overtreatment may increase risk of adverse cardiovascular events including angina and arrhythmia; avoid use in patients who are at risk for arrhythmias. Chronic untreated hypothyroidism predisposes patients to cardiovascular disease (ATA [Jonklaas 2014]; Razvi 2018).

• Diabetes: Use with caution in patients with diabetes mellitus (may worsen glycemic control).

• Myxedema: Use with caution in patients with myxedema because symptoms may be exaggerated or aggravated. Myxedema coma should be treated with injectable thyroid hormone replacement products administered IV.

• Osteoporosis: Thyroid hormone overreplacement may result in increased bone resorption and decreased bone mineral density, especially in postmenopausal patients; use the lowest effective dose to achieve therapy goals.

Special populations:

• Older adults: Use with caution in older adults (eg, >60 years of age); they may be more likely to have compromised cardiovascular function. Increase dose slowly and monitor for signs/symptoms of angina.

Warnings: Additional Pediatric Considerations

May cause transient alopecia in children during first few months of therapy.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous:

Triostat: 10 mcg/mL (1 mL [DSC]) [contains alcohol, usp]

Generic: 10 mcg/mL (1 mL)

Tablet, Oral:

Cytomel: 5 mcg

Cytomel: 25 mcg, 50 mcg [scored]

Generic: 5 mcg, 25 mcg, 50 mcg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Liothyronine Sodium Intravenous)

10 mcg/mL (per mL): $528.75

Tablets (Cytomel Oral)

5 mcg (per each): $0.46

25 mcg (per each): $0.64

50 mcg (per each): $1.07

Tablets (Liothyronine Sodium Oral)

5 mcg (per each): $0.79 - $2.20

25 mcg (per each): $1.04 - $2.89

50 mcg (per each): $1.59 - $4.41

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Cytomel: 5 mcg, 25 mcg

Generic: 5 mcg, 25 mcg

Additional Information

For purposes of conversion, levothyroxine sodium (T₄) 100 mcg is usually considered equivalent to desiccated thyroid 60 to 65 mg (1 grain), thyroglobulin 60 to 65 mg (1 grain), or liothyronine sodium (T₃) 25 mcg. However, these are rough guidelines only and do not obviate the careful re-evaluation of a patient when switching thyroid hormone preparations, including a change from one brand of levothyroxine to another.

A synthetic form of L-Triiodothyronine (T₃) can be used in patients allergic to products derived from pork or beef.

Administration: Pediatric

Oral: Administer at the same time each day.

Administration: Adult

IV: For IV use only; do not administer IM or SUBQ.

Intermittent IV administration: Administer intermittent IV doses at a rate of ≤10 mcg/minute (Ref).

Continuous IV infusion: Cadaveric organ recovery (hormonal resuscitation) (off-label use): After IV bolus administration, may administer as a continuous infusion (Ref).

Storage/Stability

Vials: Store under refrigeration at 2°C to 8°C (36°F to 46°F).

Tablets: Store at 15°C to 30°C (59°F to 86°F).

Use

Tablets: Replacement or supplemental therapy in hypothyroidism of any etiology (FDA approved in all ages); as a pituitary thyroid-stimulating hormone (TSH) suppressant in the management or prevention of nontoxic goiter, thyroid nodules, subacute or chronic autoimmune thyroiditis (Hashimoto's), and multinodular goiter (FDA approved in adults); a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy (FDA approved in adults); Note: Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis.

Parenteral: Treatment of myxedema coma/precoma (FDA approved in adults); has also been used for postcardiac surgery replacement

Note: Clinical practice guidelines do not recommend routine use of liothyronine over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]). Guidelines do not recommend using TSH suppression for benign thyroid nodules in iodine sufficient patients (ATA [Haugen 2015]). May be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.

Medication Safety Issues

Sound-alike/look-alike issues:

Liothyronine may be confused with levothyroxine

Other safety concerns:

T3 is an error-prone abbreviation (mistaken as acetaminophen and codeine [ie, Tylenol® #3])

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy

Amiodarone: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Antacids: May decrease the absorption of Thyroid Products. Risk C: Monitor therapy

Apalutamide: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 hours prior to or one hour after bile acid sequestrants, or monitor for decreased serum concentrations and clinical effects of oral thyroid products during coadministration. Risk D: Consider therapy modification

Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: Consider administering thyroid products at least 4 hours prior to calcium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use. Risk D: Consider therapy modification

Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased. Risk D: Consider therapy modification

CarBAMazepine: May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

Cardiac Glycosides: Thyroid Products may decrease the serum concentration of Cardiac Glycosides. Specifically, returning to a euthyroid state from a hypothyroid state may decrease the serum concentration of cardiac glycosides. Risk C: Monitor therapy

Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. Risk C: Monitor therapy

Furosemide: May decrease the protein binding of Thyroid Products. This may lead to a transient increase in free thyroid hormone concentrations and to a later decrease in total thyroid hormone concentrations. Risk C: Monitor therapy

Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Separate the administration of thyroid products and lanthanum by at least 4 hours. Risk D: Consider therapy modification

Nirmatrelvir and Ritonavir: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

PHENobarbital: May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. Risk C: Monitor therapy

Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use. Risk C: Monitor therapy

Primidone: May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

RifAMPin: May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

Ritonavir: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. Risk C: Monitor therapy

Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131. Management: Discontinue thyroid products before sodium iodide I-131 administration, and avoid concurrent use. Stop triiodothyronine (T3) 2 weeks before, and stop thyroxine (T4) 4 weeks before, sodium iodide I-131 administration. Risk X: Avoid combination

Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: Consider administering thyroid products at least 4 hours prior to sodium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use. Risk D: Consider therapy modification

Soybean: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. Risk C: Monitor therapy

Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Reproductive Considerations

Overt hypothyroidism increases the risk of irregular menses and infertility; thyroid replacement is recommended to normalize thyroid function in infertile patients with overt hypothyroidism who desire to become pregnant. Thyroid replacement may also be used in infertile patients with subclinical hypothyroidism using assisted reproductive techniques to become pregnant; however, liothyronine is not the preferred thyroid replacement agent (ATA [Alexander 2017]).

Pregnancy Considerations

Liothyronine has not been found to increase the risk of teratogenic or adverse effects following maternal use during pregnancy; however, normal levels of maternal thyroid hormones are required for fetal development. Untreated maternal hypothyroidism can be associated with adverse effects in both the mother and fetus, including spontaneous abortion, stillbirth, premature birth, low birth weight, impaired neurocognitive development in the offspring, abruptio placentae, gestational hypertension, and preeclampsia (ACOG 2020; ATA [Alexander 2017]).

Thyroid replacement therapy minimizes the risk of adverse pregnancy outcomes in patients with overt hypothyroidism and treatment is recommended for all patients with overt hypothyroidism during pregnancy (ACOG 2020; ATA [Alexander 2017]); however, maternal supplementation with liothyronine does not provide the fetus with sufficient concentrations of T₄ required for the developing fetal brain. Therefore, liothyronine is not the preferred treatment of maternal hypothyroidism and should not be used during pregnancy (ACOG 2020; ATA [Alexander 2017]).

Due to alterations of endogenous maternal thyroid hormones, patients with hypothyroidism who are treated with a thyroid replacement product prior to pregnancy require a dose increase as soon as pregnancy is confirmed (ATA [Alexander 2017]). Close monitoring of pregnant patients is recommended (ATA [Alexander 2017]).

Monitoring Parameters

T₃, TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; growth, bone development (children); TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T₄ remains low and TSH is within normal limits, an evaluation of "free" (unbound) T₄ is needed to evaluate further increase in dosage. Free T₄ (not TSH) should be monitored to guide treatment in patients with central hypothyroidism (ATA [Jonklaas 2014]).

In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T₄. During the first 3 years of life, total- or free-T₄ should be maintained in the upper ¹/₂ of the normal range; this should result in normalization of the TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of in utero hypothyroidism. Monitor closely for cardiac overload, arrhythmias, and aspiration from avid suckling.

Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation and accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Treated children may experience a period of catch-up growth. Monitor TSH and total or free T₄ at 2 and 4 weeks after starting treatment, every 1 to 2 months during the first year of life, every 2 to 3 months between ages 1 to 3 years, and every 3 to 12 months thereafter until growth is completed (AAP 2006; ATA [Jonklaas 2014]); repeat tests 2 weeks after any change in dosage.

Adults: Monitor TSH 4 to 6 weeks after treatment initiation or dose changes, 4 to 6 months after adequate replacement dose determined, followed by every 12 months thereafter (or more frequently depending on clinical situation) (ATA [Jonklaas 2014]).

Reference Range

Thyroid Function Tests
Lab Parameters	Age	Normal Range
T₄ (thyroxine) serum concentration	1-7 days	10.1-20.9 mcg/dL
	8-14 days	9.8-16.6 mcg/dL
	1 month to 1 year	5.5-16.0 mcg/dL
	>1 year	4.0-12.0 mcg/dL
Free thyroxine index (FTI)	1-3 days	9.3-26.6
	1-4 weeks	7.6-20.8
	1-4 months	7.4-17.9
	4-12 months	5.1-14.5
	1-6 years	5.7-13.3
	>6 years	4.8-14.0
T₃ serum concentration	Newborns	100-470 ng/dL
	1-5 years	100-260 ng/dL
	5-10 years	90-240 ng/dL
	10 years to Adult	70-210 ng/dL
T₃ uptake		35%-45%
TSH serum concentration	Cord	3-22 micro international units/mL
	1-3 days	<40 micro international units/mL
	3-7 days	<25 micro international units/mL
	>7 days	0-10 micro international units/mL

Mechanism of Action

Exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Oral: Within a few hours

Peak response: Oral: 2 to 3 days

Absorption: Oral: Well absorbed (95% in 4 hours)

Half-life elimination: 0.75 days (Brent 2011)

Excretion: Urine (primary); Feces

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AR) Argentina: T3 montpellier | Tri Iodo Tironina;
(AT) Austria: Trijodthyronin;
(AU) Australia: Tertroxin;
(BE) Belgium: Cytomel;
(BR) Brazil: Cynomel;
(CH) Switzerland: Cynomel;
(CL) Chile: Liotironina sodica;
(CO) Colombia: Cynomel | Tertroxin;
(CZ) Czech Republic: Cynomel | Tertroxin;
(DE) Germany: Thybon henning | Thyrotardin;
(EE) Estonia: Cynomel | Liothyronin | Trijodthyronin;
(EG) Egypt: Tertroxin;
(ES) Spain: Triyodotironina;
(FI) Finland: Liothyronin;
(FR) France: Cynomel | Liothyronine Dci;
(GB) United Kingdom: Iraksin | Tertroxin;
(GR) Greece: Cynomel | T3 | Triiodthyronin;
(HK) Hong Kong: Tertroxin;
(HU) Hungary: Liothyronin | Thybon;
(IE) Ireland: Tertroxin;
(IL) Israel: Cytomel | Tertroxin | Ti-tre;
(IN) India: Linorma t3;
(IT) Italy: Cineteo | Ti-tre | Tivister;
(JP) Japan: Thyronamin | Thyronin;
(KR) Korea, Republic of: Cylonin | Cytomel | Tertroxin;
(LT) Lithuania: Liothyronine | Tertroxin | Thybon;
(LV) Latvia: Cynomel | Liothyronine | Tertroxin | Triiodthyronin | Trijodthyronin;
(MX) Mexico: Cynomel | Triyotex;
(MY) Malaysia: Cytomel;
(NL) Netherlands: Cytomel | Liothyronine natrium Global Farma;
(NO) Norway: Cytomel | Liothyronin;
(NZ) New Zealand: Tertroxin;
(PE) Peru: Cetyrol | Cynomel;
(PH) Philippines: Cytomel | Tertroxin;
(PL) Poland: Cynomel | Thybon;
(PR) Puerto Rico: Cytomel | Liothyronine sod.;
(PT) Portugal: Cynomel | Neo-tiroimade;
(RU) Russian Federation: Triiodthyronin;
(SE) Sweden: Liothyronin;
(SG) Singapore: Tertroxin;
(SI) Slovenia: Thybon;
(SK) Slovakia: Tertroxin | Tri Iodo Tironina;
(TH) Thailand: Tertroxin;
(TR) Turkey: Tiromel;
(TW) Taiwan: Cytomel | Tertroxin | Thyronamin;
(UA) Ukraine: Triiodthyronin;
(UY) Uruguay: Liotironina;
(VE) Venezuela, Bolivarian Republic of: Cynomel | Tertroxin;
(ZA) South Africa: Tertroxin

Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315-389. doi:10.1089/thy.2016.0457 [PubMed 28056690]
Altshuler LL, Bauer M, Frye MA, et al. Altshuler Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617-1622. [PubMed 11578993]
American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al, "Update of Newborn Screening and Therapy for Congenital Hypothyroidism," Pediatrics, 2006, 117(6):2290-303. [PubMed 16740880]
American College of Obstetricians and Gynecologists (ACOG). Thyroid disease in pregnancy: ACOG practice bulletin, no. 223. Obstet Gynecol. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893 [PubMed 32443080]
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd edition. November 2010. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
Aronson R, Offman HJ, Joffe RT, Naylor CD. Aronson Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-848. [PubMed 8792761 ]
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry; Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334-385. [PubMed 23879318]
Brent GA, Koenig RJ. Chapter 39. Thyroid and Anti-Thyroid Drugs. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill Medical; 2011.
Chowdhury D, Ojamaa K, Parnell VA, et al, "A Prospective Randomized Clinical Study of Thyroid Hormone Treatment After Operations for Complex Congenital Heart Disease," J Thorac Cardiovasc Surg, 2001, 122(5):1023-5 [PubMed 11689811]
Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2008;11(5):685-699. [PubMed 18047754]
Cytomel (liothyronine sodium) [prescribing information]. New York, NY: Pfizer Inc; July 2019.
Cytomel (liothyronine sodium) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2017.
Dahlberg PA, Karlsson FA, Wide L. Triiodothyronine intoxication. Lancet. 1979;2(8144):700. doi:10.1016/s0140-6736(79)92105-6 [PubMed 90795]
Dimmick S, Badawi N, Randell T. Thyroid hormone supplementation for the prevention of morbidity and mortality in infants undergoing cardiac surgery (review). Cochrane Database Syst Rev. 2008;2:1-25.
Filetti S, Durante C, Hartl D, et al; ESMO Guidelines Committee. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856-1883. doi:10.1093/annonc/mdz400 [PubMed 31549998]
Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888-3921. [PubMed 27736313]
Gahart BL, Nazareno AR. 2014 Intravenous Medications: A Handbook for Nurses and Health Professionals. 30th ed. St Louis, MO: Elsevier/Mosby; 2014:745-747.
Garber KR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028. [PubMed 23246686]
Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res. 2012;46(11):1406-1413. [PubMed 22964160]
Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update. Endocr Pract. 2016;22(5):622-639. doi: 10.4158/EP161208.GL. [PubMed 27167915]
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020. [PubMed 26462967]
Helfand M and Crapo LM, “Monitoring Therapy in Patients Taking Levothyroxine,” Ann Intern Med, 1990, 113(6):450-4. [PubMed 2143640]
James SR, Ranasinghe AM, Venkateswaran R, McCabe CJ, Franklyn JA, Bonser RS. The effects of acute triiodothyronine therapy on myocardial gene expression in brain stem dead cardiac donors. J Clin Endocrinol Metab. 2010;95(3):1338-1343. [PubMed 20080850]
Johnson DG and Campbell S, “Hormonal and Metabolic Agents,” Geriatric Pharmacology, Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.
Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028 [PubMed 25266247]
Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid. 2021;31(2):156-182. doi:10.1089/thy.2020.0720 [PubMed 33276704]
Kotloff RM, Blosser S, Fulda GJ, et al. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement organizations consensus statement. Crit Care Med. 2015;43(6):1291-1325. doi:10.1097/CCM.0000000000000958 [PubMed 25978154]
Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-30; quiz 1665. [PubMed 16946176]
Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantation. 2014;98(10):1119-1127. [PubMed 25405914]
Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215-228. doi: 10.1159/000356507. [PubMed 24783053]
Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol. 2018;71(16):1781‐1796. doi:10.1016/j.jacc.2018.02.045 [PubMed 29673469]
Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted Organs. Transplantation. 2003a;75(4):482-487. doi:10.1097/01.TP.0000045683.85282.93 [PubMed 12605114]
Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003b;75(8):1336-1341. [PubMed 12717226]
Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant. 2002;2(8):701-711. [PubMed 12243491]
Rosenthal LJ, Goldner WS, O'Reardon JP. T3 augmentation in major depressive disorder: safety considerations. Am J Psychiatry. 2011;168(10):1035-1040. [PubMed 21969047]
Ross DS. Myxedema coma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 29, 2022b.
Ross DS. Treatment of primary hypothyroidism in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 21, 2022a.
Salim A, Martin M, Brown C, et al, “Using Thyroid Hormone in Brain-Dead Donors to Maximize the Number of Organs Available for Transplantation,” Clin Transplant, 2007, 21(3):405-9. [PubMed 17488392 ]
Sanders LR, “Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly,” Geriatric Medicine, 1990, 475-87.
Sawin CT, Geller A, Hershman JM, et al, “The Aging Thyroid. The Use of Thyroid Hormone in Older Persons,” JAMA, 1989, 261(18):2653-5. [PubMed 2709545]
Triostat (liothyronine sodium) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; received August 2017.
Watts NB, “Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine,” Arch Intern Med, 1989, 149(2):309-12. [PubMed 2644903]
Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. doi:10.1159/000339444 [PubMed 24782999]
Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations: March 28-29, 2001, Crystal City, Va. Circulation. 2002;106(7):836-841. doi:10.1161/01.cir.0000025587.40373.75 [PubMed 12176957]

Topic 12557 Version 261.0

خرید پکیج

Liothyronine: Pediatric drug information